Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

immunity · Mechanism Report

Does broad Borrelia IgG reactivity indicate prior exposure rather than active infection?

Broad Borrelia IgG reactivity is best interpreted as evidence of prior antigen exposure and immune memory, not as proof of active infection.

UnsupportedSeptember 23, 20266 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Broad Borrelia IgG reactivity across multiple antigens is consistent with prior antigen exposure and durable immune memory, but antibody reactivity alone does not establish active infection.

laying out figure…
1 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says that IgG reactivity across multiple Borrelia antigens can persist long after infection and therefore reflects prior immune recognition. The mechanism framing also notes that this pattern cannot, by itself, date infection or confirm ongoing infection, and that serially rising responses in a compatible illness are more informative.

Verified conclusion

Broad Borrelia IgG reactivity is most reliably interpreted as evidence of prior immune recognition, not as a stand-alone marker of current infection. This distinction is particularly important when testing is obtained outside a clinically compatible, exposure-plausible syndrome.

Serologic interpretation

  • Multi-antigen IgG reactivity is consistent with prior Borrelia antigen exposure and durable humoral memory. In standard two-tier testing, an IgG immunoblot requires reactivity to at least five specified antigens.
  • Persistence is common long after illness resolution: 10–20 years after treated Lyme disease, IgG remained positive in 25% of people with prior early Lyme disease and 62% with prior Lyme arthritis. Persistent responses included DbpA, BmpA, FlaB, p58, and p93.
  • C6/VlsE-directed IgG may decline after treatment but can remain positive, so neither broad IgG reactivity nor a residual C6 result can date infection, demonstrate treatment failure, or function as a test of cure.

Active-infection assessment

  • A single positive antibody result—including broad IgG reactivity—does not demonstrate viable organisms or active B. burgdorferi infection. Serology measures host response, and both IgG and sometimes IgM may persist for years or decades after eradication or successful therapy.
  • Interpretation requires compatible manifestations, symptom timing, and epidemiologic exposure likelihood. In a low-incidence cohort without endemic travel, serology’s positive predictive value was only 10%.
  • Serial evidence can add context: a broad, evolving IgG response with rising titers during a compatible illness supports active infection, but is not established by one sample. Isolated IgM after >30 days of symptoms is particularly unreliable.

Bottom line

  • Broad Borrelia IgG strongly supports previous antigen exposure and durable immune memory, but alone cannot establish active infection or persistent bacteria; clinical syndrome and exposure context determine its practical meaning.

References

  1. C6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis | Journal of Clinical Microbiology — journals.asm.org ↗
  2. Diagnostic validation of novel Borrelia antigens discovered by whole-proteome microarray: Advancing early detection and test of cure for Lyme disease — cell.com ↗
  3. Persistence of the Antibody Response to the VlsE Sixth Invariant Region (IR6) Peptide of Borrelia burgdorferi after Successful Antibiotic Treatment of Lyme Disease — academic.oup.com ↗
  4. Laboratory Diagnosis of Lyme Borreliosis - PMC — pmc.ncbi.nlm.nih.gov ↗
  5. Testing and Diagnosis for Lyme disease — cdc.gov ↗
  6. Suggested Reporting Language, Interpretation and Guidance for Lyme Disease Serologic Testing Results — cdc.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Unsupported4 sourcesDoes a positive Anaplasma IgM alone diagnose active anaplasmosis?→Plausible13 sourcesCan gliotoxin and mycophenolic acid alter immune processes without proving neural autoimmunity?→